Evidence map›Paper›PMID 40615690›Full record

ReviewOncogene2025

Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer.

Priya Jayachandran, Andrew Elliott, Shivani Soni, Francesca Battaglin, Pooja Mittal, Sandra Algaze, Jae Ho Lo, Yan Yang, Karam Ashouri, Evanthia T Roussos Torres and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Priya JayachandranDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Priya.Jayachandran@med.usc.edu.ORCID http://orcid.org/0009-0002-2480-4057
Andrew ElliottCaris Life Sciences, Phoenix, AZ, USA.ORCID http://orcid.org/0000-0001-8494-8031
Shivani SoniDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-6368-4177
Francesca BattaglinDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Pooja MittalDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Sandra AlgazeDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jae Ho LoDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Yan YangDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-7883-0798
Karam AshouriDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0000-1825-1033
Evanthia T Roussos TorresDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-0740-5102
Wu ZhangDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Joshua MillsteinDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-7961-8943
Lin ZhangDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-0018-3903
Jian YuDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-4021-1000
Heinz-Josef LenzDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-2178-9568

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA014089
6 · The paper itself

Abstract

RAS is an oncogene that is commonly mutated in colorectal cancer (CRC). It has been considered a negative feature both due to its impact on prognosis and due to the shallow interface of oncogenic Ras for therapeutic targeting. Newer pan-Ras inhibitor strategies include improved direct targeting of RAS, blockade of downstream effectors, immunotherapy approaches, and even the inclusion of anti-EGFR drugs. Polo-like Kinase 1 (PLK1) is a serine/threonine protein kinase that controls multiple aspects of the cell-cycle. It is upregulated in CRC and has become an important therapeutic target in KRAS mutant CRC, with several PLK1 inhibitors currently in various phases of development and testing. As with other targeted therapies, resistance remains a problem and combination strategies may be beneficial. This review discusses pan-RAS inhibitors and PLK1 in the context of CRC. It discusses RAS' many roles, its associated pathways and relationship to cancer progression, the current status of existing inhibitors, and future strategies for targeting in cancer therapy. The wide-ranging impacts of RAS provide a basis to better understand and fight against CRC.

Indexed as

Antineoplastic AgentsCell Cycle ProteinsColorectal NeoplasmsProtein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteinsras ProteinsAnimalsHumansMolecular Targeted TherapyPolo-Like Kinase 1Antineoplastic AgentsCell Cycle ProteinsPolo-Like Kinase 1Protein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteinsras Proteins

Identifiers

PMID40615690
PMCPMC12277178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.